<DOC>
	<DOC>NCT00250471</DOC>
	<brief_summary>The primary purpose of this study was to compare the efficacy and safety of bivalirudin to eptifibatide (with or without unfractionated heparin or enoxaparin)given to subjects at high risk for heart attack and other cardiovascular complications who will undergo surgery to open up blocked arteries in the heart.</brief_summary>
	<brief_title>PROTECT-TIMI 30 Trial</brief_title>
	<detailed_description>Platelet inhibitor drugs</detailed_description>
	<mesh_term>Angina, Unstable</mesh_term>
	<mesh_term>Fibrinolytic Agents</mesh_term>
	<criteria>Chest paing/discomfort that occurs at rest and lasts at least 10 minutes and have at least one of the following highrisk features: diabetes elevated cardiac proteins in the blood (indicating acute coronary syndrome) Be willing and able to give informed consent uncontrolled hypertension cardiac episode (heart attack) within the previous 24 hours before randomization into the trial prior heart surgery (PCI) within the previous 2 weeks before randomizing in the trial any electorcardogram (ECG) finding that make the Holter monitor for ischemia unable to read</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2005</verification_date>
	<keyword>GP IIb/IIIa inhibitors</keyword>
	<keyword>eptifibatide</keyword>
	<keyword>Anti-thrombotic agents</keyword>
</DOC>